Nivolumab-induced small bowel obstruction and perforation: a rare but life-threatening side effect of immunotherapy
- 1 February 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Emergency Radiology
- Vol. 27 (1), 107-110
- https://doi.org/10.1007/s10140-019-01731-x
Abstract
We present a case of a 58-year-old female with anti-PD-1 immunotherapy-related small bowel perforation. The patient was on long-term therapy with nivolumab for metastatic non-small cell lung cancer. She presented to the emergency department with acute abdominal pain, in which the CT revealed a short segment of dilated distal ileum proximal to a very short segment of bowel with mural thickening and a perforation near the transition point. The patient underwent subsequent laparotomy, which confirmed the CT findings and revealed a short-segment of friable and dilated loop of distal ileum proximal to a stricture and a small perforation at the transition point. Pathological analysis revealed mural thickening at the site of stricture without evidence of malignancy with focal necrosis and perforation at the transition point. Bowel perforation in the setting of anti-PD-1 immunotherapy is rare, but life-threatening complication, and should be considered in oncology patients on immunotherapy presenting with severe abdominal pain.This publication has 9 references indexed in Scilit:
- The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature reviewBMC Gastroenterology, 2018
- Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experienceTranslational Lung Cancer Research, 2018
- Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patientsMedicine, 2017
- Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case reportSurgical Case Reports, 2017
- Biological agents in gastrointestinal cancers: adverse effects and their managementJournal of Gastrointestinal Oncology, 2017
- Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor TherapyFrontiers in Pharmacology, 2017
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Adverse Events of Monoclonal Antibodies Used for Cancer TherapyBioMed Research International, 2015
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabJournal of Clinical Oncology, 2014